May 17th 2024
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications
February 10th 2021The FDA has granted breakthrough therapy designation to asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who have been previously treated with 2 or more tyrosine kinase inhibitors; or who harbor the T315I mutation.
Preemptive Tocilizumab Decreases CRS After Tisagenlecleucel Administration in Pediatric B-Cell ALL
February 8th 2021Tisagenlecleucel has already received FDA approval and is now available at some treatment centers, thereby imparting significance to results about tocilizumab use in patients at-risk for severe cytokine release syndrome.
Study Suggests a High Charlson Comorbidity Index Score Negatively Impacts OS, RS in CLL
February 3rd 2021When also considering age and Rai score, the effect of Charlson comorbidity index score on mortality was found to be statistically nonsignificant for patients with chronic lymphocytic leukemia, although higher scores were associated with worse overall and relative survival.
Optimal Number of Treatment Courses Explored in Younger Patients with AML
February 1st 2021Based on the results of an analysis, investigators suggested that if high-dose daunorubicin and cytarabine is the selected consolidation treatment for younger patients with acute myeloid leukemia, a fourth course of therapy is likely beneficial for most.
Integrated Palliative and Oncology Care Improved QOL, End-of-Life Care for Patients with AML
January 25th 2021Data published in JAMA Oncology found boosts in quality of life in addition to improvements in depression, anxiety, and posttraumatic stress symptoms for patients with acute myeloid leukemia receiving integrated palliative and oncology care.
Acalabrutinib Meets Primary End Point Versus Ibrutinib in Previously Treated, High-Risk CLL
January 25th 2021Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program.
TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL
January 19th 2021Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.
Various Diagnostic Criteria by PET/CT May Assist in Predicting Richter Syndrome in CLL
January 14th 2021A recent study revealed that by using standardized uptake value thresholds as determined by 2-[18F]-FDG PET/CT, investigators were able to predict the occurrence of Richter syndrome in patients with CLL.
Patients with Ph- B-cell ALL May Benefit From Addition of Blinatumomab to Chemotherapy Combo
January 13th 2021The addition of the monoclonal antibody blinatumomab to hyper-CVAD could represent a potential option for extending remission times in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.
Phase 3 QUAZAR AML-001 Trial Finds Oral Azacitidine Extends Survival in Older Adults with AML
January 12th 2021“Based on the results of the QUAZAR study, it is very exciting to think that, by taking a tablet that is relatively well tolerated, we can help reduce relapse risk and improve survival,” lead study author Andrew H. Wei, MB, BS, PhD, said in a press release.
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML
December 19th 2020The FDA approved the supplemental new drug application for ponatinib (Iclusig) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.